A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to "modestly" greater improvements in itchiness over placebo, but was associated with adverse events, a randomized ...

New York, NY (February 8, 2023) – Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no ...

STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

Notalgia paresthetica is a neuropathic disorder characterized by pruritus in a circumscribed region of the upper back. Difelikefalin, a selective kappa opioid receptor agonist, has shown efficacy in ...

STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...

Patients with persistent upper-back itch from notalgia paresthetica may get some relief with oral difelikefalin (Korsuva), phase 2 data from a randomized, double-blinded placebo-controlled trial ...

Considering taking supplements to treat Notalgia paresthetica? Below is a list of common natural remedies used to treat or reduce the symptoms of Notalgia paresthetica. Follow the links to read common ...

A recently published case series illustrates how a treatment approved last year for two conditions associated with pruritus could be useful in alleviating itch in patients with a broad variety of ...

– Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. , a development-stage ...